毛细胞白血病一线皮下克拉屈滨治疗后的前瞻性长期随访:一项SAKK试验
该研究分析了瑞士临床癌症研究组(SAKK)1993至2005年间开展的3项前瞻性多中心临床试验中221例经典型毛细胞白血病(HCL)患者接受皮下克拉屈滨治疗的长期结局。中位总生存未达到,既往贫血、较高ECOG评分和较高年龄与较差总生存相关,而24和36个月早期进展对总生存无显著影响。53例(23.7%)需二线治疗,44例(19.9%)发生第二原发恶性肿瘤,但与匹配的正常瑞士人群相比第二原发恶性肿瘤发生率未增加,HCL患者生存略差(P = .036)。
要点
- 皮下克拉屈滨治疗HCL长期结局优秀,多数患者1个周期即可达到长期疾病控制。
- 53例(23.7%)需二线治疗,中位时间5年,一线再治疗主要为克拉屈滨单药(66%)。
- 44例(19.9%)发生第二原发恶性肿瘤,中位发生时间5.7年,为死亡主因(14例;27.5%)。
核心结论
- 皮下克拉屈滨治疗HCL的结局优秀,多数患者1个周期皮下克拉屈滨足以实现长期疾病控制。
研究设计与样本
- 分析瑞士临床癌症研究组(SAKK)开展的3项前瞻性多中心临床试验,1993年至2005年间共纳入221例经典型HCL患者,接受皮下克拉屈滨治疗并长期随访。
主要发现
- 自治疗开始的中位总生存未达到。
- 多变量分析中,既往贫血、较高ECOG评分和较高年龄与较差总生存相关,而24和36个月早期进展对总生存无显著影响。
- 53例(23.7%)患者需二线治疗,中位时间5(范围0.2-20.4)年,首次再治疗主要为克拉屈滨单药(66%)或利妥昔单抗(15.1%)或两药联合(15.1%)。
- 44例(19.9%)患者发生第二原发恶性肿瘤,中位发生时间5.7(范围0.01-17.5)年,第二原发恶性肿瘤为死亡主因(14例;27.5%)。
- 与匹配的正常瑞士人群相比,第二原发恶性肿瘤发生率未增加;但HCL患者生存略差(P = .036)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Although there are excellent long-term data for intravenous application, similar data regarding subcutaneous administration are lacking. We therefore analyzed the long-term outcome of 3 prospective multicenter clinical trials on subcutaneous cladribine performed by the Swiss Group for Clinical Cancer Research (SAKK), which recruited 221 patients with classical HCL between 1993 and 2005. Median overall survival from start of treatment was not reached. Pretreatment anemia, higher Eastern Cooperative Oncology Group score, and higher age were associated with poorer overall survival in multivariable analysis, whereas early progression at 24 and 36 months had no significant impact on overall survival. Second-line treatment was necessary in 53 (23.7%) patients after a median of 5 (range, 0.2-20.4) years, and first retreatment was mainly monotherapy with cladribine (66%) or rituximab (15.1%) or a combination of these drugs (15.1%). A total of 44 (19.9%) patients developed second primary malignancies with a median time to occurrence of 5.7 (range, 0.01-17.5) years. Second primary malignancies were the main cause for death (14; 27.5%). Compared with a matched normal Swiss population, the incidence of second primary malignancies was not increased. However, survival of patients with HCL was slightly inferior by comparison (P = .036). In conclusion, the outcome of HCL patients treated with subcutaneous cladribine is excellent, and in most patients, 1 cycle of subcutaneous cladribine is sufficient for long-term disease control.
引用
- Benz R, Arn K, Andres M, et al. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv. 2020. PMID: 32777066. doi:10.1182/bloodadvances.2020002160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。